|
Home
|
E-Submission
|
Sitemap
|
Editorial Office
|
Aims and Scope
About the Journal
Editorial Board
Open Access
Best Reviewer Awardees
Article Processing Charge
Editorial Office
Instructions for Authors
Research and Publication Ethics
Checklist
E-Submission
Copyright Transfer Agreement
All issues
Accepted Articles
Epub Ahead-of Print Articles
Current Issue
Most Read Articles
Most Cited Articles
Cancer Research and Treatment
Search
Author Index
Cancer Research and Treatment
Search
> Browse Articles > Search
Lung and Thoracic cancer
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus
Bevacizumab
in Advanced
EGFR
-Mutant Lung Adenocarcinoma
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang
Cancer Res Treat.
2022;54(2):434-444. Published online August 2, 2021 DOI:
https://doi.org/10.4143/crt.2021.671
Cited By 7
Gastrointestinal Cancer
Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without
Bevacizumab
in Patients with Metastatic Colorectal Cancer: A Meta-Analysis
Toshikazu Moriwaki, Masahiko Gosho, Akinori Sugaya, Takeshi Yamada, Yoshiyuki Yamamoto, Ichinosuke Hyodo
Cancer Res Treat.
2021;53(3):703-713. Published online December 1, 2020 DOI:
https://doi.org/10.4143/crt.2020.805
Bevacizumab
Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
Yeonjoo Choi, Bhumsuk Keam, Miso Kim, Shinkyo Yoon, Dalyong Kim, Jong Gwon Choi, Ja Young Seo, Inkeun Park, Jae Lyun Lee
Cancer Res Treat.
2019;51(4):1549-1556. Published online March 25, 2019 DOI:
https://doi.org/10.4143/crt.2019.086
Cited By 29
A Single Arm, Phase II Study of Simvastatin Plus XELOX and
Bevacizumab
as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
Youjin Kim, Tae Won Kim, Sae Won Han, Joong Bae Ahn, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Cancer Res Treat.
2019;51(3):1128-1134. Published online November 21, 2018 DOI:
https://doi.org/10.4143/crt.2018.379
Cited By 8
Post-
bevacizumab
Clinical Outcomes and the Impact of Early Discontinuation of
Bevacizumab
in Patients with Recurrent Malignant Glioma
Yongjun Cha, Yu Jung Kim, Se-Hoon Lee, Tae-Min Kim, Seung Hong Choi, Dong-Wan Kim, Chul-Kee Park, Il Han Kim, Jee Hyun Kim, Eunhee Kim, Byungse Choi, Chae-Yong Kim, In Ah Kim, Dae Seog Heo
Cancer Res Treat.
2017;49(1):129-140. Published online May 18, 2016 DOI:
https://doi.org/10.4143/crt.2015.466
Cited By 4
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for
Bevacizumab
in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial
Yeo-Eun Kim, Bio Joo, Mi-Suk Park, Sang Joon Shin, Joong Bae Ahn, Myeong-Jin Kim
Cancer Res Treat.
2016;48(4):1210-1221. Published online March 17, 2016 DOI:
https://doi.org/10.4143/crt.2015.374
Cited By 11
Intestinal Perforation in Colorectal Cancers Treated with
Bevacizumab
(Avastin®)
Young Il Choi, Seung Hyun Lee, Byung Kwon Ahn, Sung Uhn Baek, Seun Ja Park, Yang Soo Kim, Seong Hoon Shin
Cancer Res Treat.
2008;40(1):33-35. Published online March 31, 2008 DOI:
https://doi.org/10.4143/crt.2008.40.1.33
Cited By 18
1
> Browse Articles > Search
